← All trials
NCT02296541
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2014
- Primary completion
- Nov 1, 2016
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 105
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of LausanneCollaborator
- Harvard UniversityStudy chair
- HIV Vaccine Trials NetworkCollaborator
- Duke UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.